DSS Imagetech Charts Growth Path Through AI-Enabled Diagnostics and Reproductive Care Expansion
核心洞察
DSS Imagetech (搜索) has evolved from a diagnostic equipment provider into a comprehensive healthcare solutions partner spanning microscopy, clinical diagnostics, and R&D.
The company identifies advanced imaging, digital pathology, molecular diagnostics, AI-enabled solutions, and reproductive care as its key growth segments.
Through its Hana Health (搜索) division, DSS Imagetech (搜索) is investing in AI-enabled embryo assessment and time-lapse incubation systems to improve fertility treatment precision.
The Indian medical diagnostics sector is undergoing a fundamental transformation from standalone equipment to integrated, data-driven ecosystems, and DSS Imagetech (搜索) is positioning itself at the center of this shift. In an exclusive interview with Indian Pharma Post, Managing Director Ajay Kandhari outlined the company's strategic roadmap, highlighting artificial intelligence, automation, and reproductive care as the pillars of future growth.
A Legacy of Diagnostic Innovation
DSS Imagetech (搜索) began as a provider of advanced diagnostic and imaging technologies and has steadily evolved into what Kandhari describes as "a comprehensive healthcare solutions partner." The company has expanded its portfolio across microscopy, clinical diagnostics, medical equipment, and research and development, with the stated goal of enabling healthcare providers to deliver "more accurate, efficient, and patient-centric care."
Reflecting on the industry's evolution, Kandhari noted that "advances in digital imaging, automation, AI-assisted diagnostics, and precision medicine have significantly improved diagnostic accuracy, speed, and clinical outcomes." He also pointed to a growing emphasis on early diagnosis, preventive healthcare, and personalized treatment pathways as defining trends reshaping the sector.
Growth Drivers: AI, Digital Pathology, and Reproductive Care
Kandhari identified five segments expected to contribute most significantly to the company's business in the coming years: advanced imaging, digital pathology, molecular diagnostics, AI-enabled diagnostic solutions, and reproductive care. The IVF sector, in particular, "continues to see significant momentum, with the help of increased awareness, technological improvements, and acceptance of new treatments around the globe continuing to drive strong growth," he said.
Hana Health (搜索) and the AI-Enabled Fertility Lab
Central to the company's AI strategy is Hana Health (搜索) by DSS Imagetech (搜索), a division focused on advancing reproductive healthcare and fertility solutions. Kandhari explained that the company is investing in technologies including AI-enabled embryo assessment and time-lapse incubation systems, which allow clinicians to "monitor embryo development continuously, analyse large volumes of developmental data, and make more informed embryo selection decisions."
According to Kandhari, these tools not only enhance precision but also "help standardise processes and reduce subjectivity in fertility treatments." Automation plays an equally critical role, with automated workflows and intelligent monitoring systems helping fertility specialists "optimise operational efficiency while maintaining the highest standards of care."
Beyond fertility, Kandhari emphasized the broader role of healthcare data analytics: "By leveraging data analytics and AI-driven insights, healthcare providers can better understand patient needs, predict outcomes, and deliver more tailored interventions."
Competitive Differentiation and Market Strategy
Addressing the competitive landscape in India's diagnostic technology market, Kandhari attributed DSS Imagetech (搜索)'s differentiation to "its ability to combine a diversified mix of globally recognized technologies with strong technical expertise, service support, and deep customer relationships cultivated over decades."
On the challenge of balancing innovation with affordability in India's price-sensitive healthcare environment, Kandhari was unequivocal: "Our objective is to make innovation translate into improved patient outcomes across a large number of patients." The company works with global partners and healthcare providers to introduce technologies that are "clinically relevant, operationally efficient, and financially viable," aiming to "improve the accessibility of advanced diagnostics while not sacrificing the quality of those services."
As Hana Health (搜索) continues to bring AI and automation technologies to the Indian market, Kandhari affirmed the division's commitment to "enabling clinicians to make evidence-based decisions while improving the overall patient experience and advancing the future of reproductive medicine."